HK1155203A1 - Conjugates prepared with aggregate-free proteins - Google Patents

Conjugates prepared with aggregate-free proteins

Info

Publication number
HK1155203A1
HK1155203A1 HK11109405.7A HK11109405A HK1155203A1 HK 1155203 A1 HK1155203 A1 HK 1155203A1 HK 11109405 A HK11109405 A HK 11109405A HK 1155203 A1 HK1155203 A1 HK 1155203A1
Authority
HK
Hong Kong
Prior art keywords
conjugates prepared
protein
aggregate
large aggregates
conjugates
Prior art date
Application number
HK11109405.7A
Other languages
English (en)
Chinese (zh)
Inventor
Merry R Sherman
Mark G P Saifer
L David Williams
Michael S Hershfield
Susan J Kelly
Original Assignee
Mountain View Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain View Pharmaceuticals filed Critical Mountain View Pharmaceuticals
Publication of HK1155203A1 publication Critical patent/HK1155203A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK11109405.7A 2000-02-10 2010-10-27 Conjugates prepared with aggregate-free proteins HK1155203A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/501,730 US6783965B1 (en) 2000-02-10 2000-02-10 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Publications (1)

Publication Number Publication Date
HK1155203A1 true HK1155203A1 (en) 2012-05-11

Family

ID=23994789

Family Applications (4)

Application Number Title Priority Date Filing Date
HK03109064.9A HK1056742A1 (en) 2000-02-10 2003-12-11 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
HK11109405.7A HK1155203A1 (en) 2000-02-10 2010-10-27 Conjugates prepared with aggregate-free proteins
HK10110105.9A HK1143989A1 (en) 2000-02-10 2010-10-27 Conjugates prepared with aggregate-free proteins
HK10111402.7A HK1144701A1 (en) 2000-02-10 2010-12-08 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK03109064.9A HK1056742A1 (en) 2000-02-10 2003-12-11 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK10110105.9A HK1143989A1 (en) 2000-02-10 2010-10-27 Conjugates prepared with aggregate-free proteins
HK10111402.7A HK1144701A1 (en) 2000-02-10 2010-12-08 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Country Status (28)

Country Link
US (3) US6783965B1 (xx)
EP (3) EP1254237B1 (xx)
JP (2) JP5165826B2 (xx)
KR (3) KR20070092329A (xx)
CN (2) CN101735991B (xx)
AT (1) ATE463576T1 (xx)
AU (3) AU2001249975B2 (xx)
BE (1) BE2013C045I2 (xx)
BR (1) BRPI0108386B8 (xx)
CA (1) CA2398679C (xx)
CY (3) CY1110142T1 (xx)
CZ (1) CZ304864B6 (xx)
DE (1) DE60141742D1 (xx)
DK (3) DK1254237T3 (xx)
ES (2) ES2524153T3 (xx)
FR (1) FR13C0036I2 (xx)
HK (4) HK1056742A1 (xx)
HU (1) HU227127B1 (xx)
IL (3) IL151065A0 (xx)
LU (1) LU92237I2 (xx)
MX (1) MXPA02007545A (xx)
NZ (1) NZ520434A (xx)
PL (1) PL208064B1 (xx)
PT (2) PT2305819E (xx)
RU (3) RU2352354C2 (xx)
TW (2) TW200914617A (xx)
WO (1) WO2001059078A2 (xx)
ZA (1) ZA200207206B (xx)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
RU2246318C2 (ru) * 1998-08-06 2005-02-20 Маунтэн Вью Фармасьютикэлз, Инк. Конъюгаты peg-уриказы и их использование
ES2404074T3 (es) 1998-08-06 2013-05-23 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso
EP1100880B1 (en) 1998-08-06 2010-10-06 Duke University Urate oxidase
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
WO2003002716A2 (en) 2001-06-28 2003-01-09 Mountain View Pharmaceuticals, Inc. Polymer stabilized proteinases
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050502A (xx) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
EP2336162A1 (en) * 2003-05-12 2011-06-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
EP1628686A2 (en) 2003-05-12 2006-03-01 Affymax, Inc. Spacer moiety for poly (ethylene glycol)-modified peptides
NZ543935A (en) * 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006060148A2 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008534640A (ja) * 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
PL3321359T3 (pl) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Wariantowe postacie oksydazy moczanowej i ich zastosowanie
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
MX2007012548A (es) * 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
EP1883425A1 (en) * 2005-05-23 2008-02-06 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
HU230758B1 (hu) * 2006-04-12 2018-03-28 Crealta Pharmaceuticals LLC 100% Fehérjék tisztítása kationos felületaktív anyaggal
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
CN102307594A (zh) 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
EP3482768A1 (en) 2009-06-25 2019-05-15 Horizon Pharma Rheumatology LLC Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
HUE039605T2 (hu) 2010-01-06 2019-01-28 Dyax Corp Plazma kallikreint kötõ proteinek
WO2011127393A2 (en) 2010-04-08 2011-10-13 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
DK3003358T3 (da) * 2013-06-07 2021-06-21 Allena Pharmaceuticals Inc Sammensætninger og anordninger til dialyse
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
WO2015148790A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US11098289B2 (en) 2015-05-15 2021-08-24 Medimmune, Llc Uricase sequences and methods of treatment
MX2018004586A (es) 2015-10-15 2018-08-16 Agios Pharmaceuticals Inc Terapia de combinacion para tratar tumores malignos.
LT3362065T (lt) 2015-10-15 2024-07-25 Les Laboratoires Servier Kompleksinė terapija, apimanti ivosidenibą, citarabiną ir daunorubiciną arba idarubiciną, skirta ūminės mielogeninės leukemijos gydymui
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
EP3655527A4 (en) 2017-07-07 2021-06-16 Allena Pharmaceuticals Inc. RECOMBINANT URICASE ENZYME
US20190309269A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109055260B (zh) * 2018-08-08 2021-11-09 淮海工学院 弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (xx)
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
CH657141A5 (de) 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
JP2524586B2 (ja) * 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
JPH085506B2 (ja) * 1986-08-25 1996-01-24 日東製器株式会社 缶容器
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5955336A (en) * 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
KR0159107B1 (ko) 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
JP3693671B2 (ja) * 1991-03-15 2005-09-07 アムゲン インコーポレーテッド ポリペプチドのｐｅｇ化
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
AU6586394A (en) * 1993-04-22 1994-11-08 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU691225B2 (en) 1993-11-10 1998-05-14 Schering Corporation Improved interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
MX9704137A (es) 1994-12-07 1997-09-30 Novo Nordisk As Polipeptidos de alergenicidad reducida.
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en) 1995-06-07 1998-12-29 Chiron Corporation Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
ATE342729T1 (de) 1997-01-15 2006-11-15 Phoenix Pharmacologics Inc Modifizierter tumor-nekrosefaktor
EP1500661A1 (en) * 1998-06-01 2005-01-26 Genetech, Inc. Separation of protein monomers from aggregates by use of ion-exchange chromatography
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
RU2246318C2 (ru) 1998-08-06 2005-02-20 Маунтэн Вью Фармасьютикэлз, Инк. Конъюгаты peg-уриказы и их использование
EP1100880B1 (en) 1998-08-06 2010-10-06 Duke University Urate oxidase
ES2404074T3 (es) * 1998-08-06 2013-05-23 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
EP3005545A1 (en) 2013-05-24 2016-04-13 Zentrum Mikroelektronik Dresden AG Non pwm digital dc-dc converter

Also Published As

Publication number Publication date
ZA200207206B (en) 2003-05-06
TW200914617A (en) 2009-04-01
HU227127B1 (en) 2010-07-28
ES2343105T3 (es) 2010-07-23
NZ520434A (en) 2004-05-28
AU2009212900A1 (en) 2009-10-01
EP2196538A1 (en) 2010-06-16
IL151065A (en) 2008-12-29
HUP0204544A2 (en) 2003-05-28
EP2305819A1 (en) 2011-04-06
CN100491532C (zh) 2009-05-27
RU2557318C9 (ru) 2015-09-10
HK1143989A1 (en) 2011-01-21
CZ304864B6 (cs) 2014-12-17
PL358539A1 (en) 2004-08-09
US7927852B2 (en) 2011-04-19
CN1423699A (zh) 2003-06-11
ES2524153T3 (es) 2014-12-04
IL193365A (en) 2011-08-31
FR13C0036I2 (fr) 2014-05-16
JP5165826B2 (ja) 2013-03-21
PT2305819E (pt) 2015-06-01
RU2352354C2 (ru) 2009-04-20
BRPI0108386B8 (pt) 2021-05-25
MXPA02007545A (es) 2002-12-13
AU4997501A (en) 2001-08-20
BR0108386B1 (pt) 2017-10-31
US20080057048A1 (en) 2008-03-06
FR13C0036I1 (fr) 2013-08-09
EP1254237B1 (en) 2010-04-07
DK1254237T3 (da) 2010-07-19
RU2281954C2 (ru) 2006-08-20
HK1144701A1 (en) 2011-03-04
BR0108386A (pt) 2002-10-29
LU92237I2 (fr) 2013-09-03
KR101054247B1 (ko) 2011-08-08
CY1117264T1 (el) 2017-04-26
RU2006107110A (ru) 2007-09-20
AU2009212900B2 (en) 2011-12-08
HK1056742A1 (en) 2004-02-27
TWI322184B (en) 2010-03-21
CA2398679A1 (en) 2001-08-16
JP2011188861A (ja) 2011-09-29
KR20020087934A (ko) 2002-11-23
RU2557318C2 (ru) 2015-07-20
ES2343105T8 (es) 2013-07-15
KR100884724B1 (ko) 2009-02-19
CN101735991A (zh) 2010-06-16
AU2001249975B2 (en) 2006-06-08
BR0108386C1 (pt) 2011-12-20
CY2013028I1 (el) 2015-11-04
HUP0204544A3 (en) 2007-05-02
CY2013028I2 (el) 2015-11-04
IL151065A0 (en) 2003-04-10
DE60141742D1 (de) 2010-05-20
CZ20022982A3 (cs) 2003-01-15
EP1254237A2 (en) 2002-11-06
KR20070092329A (ko) 2007-09-12
IL193365A0 (en) 2009-02-11
KR20080098686A (ko) 2008-11-11
ATE463576T1 (de) 2010-04-15
BE2013C045I2 (xx) 2020-06-24
US8921064B2 (en) 2014-12-30
US6783965B1 (en) 2004-08-31
WO2001059078A3 (en) 2002-03-07
CY1110142T1 (el) 2015-01-14
CN101735991B (zh) 2013-09-11
DK2305819T3 (en) 2015-01-05
JP5341945B2 (ja) 2013-11-13
PT1254237E (pt) 2010-06-07
EP2305819B1 (en) 2014-11-12
PL208064B1 (pl) 2011-03-31
JP2003521937A (ja) 2003-07-22
DK2196538T3 (en) 2015-01-05
WO2001059078A2 (en) 2001-08-16
US20110287466A1 (en) 2011-11-24
RU2009104003A (ru) 2010-08-20
EP2196538B1 (en) 2014-10-01
CA2398679C (en) 2015-11-17

Similar Documents

Publication Publication Date Title
HK1155203A1 (en) Conjugates prepared with aggregate-free proteins
KR940019312A (ko) 폴리에틸렌 옥사이드로 개질된 단백질 및 폴리펩티드와 사이클로덱스트린의 동결 건조된 복합체
CA2064689A1 (en) Stabilized protein or peptide conjugates
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
WO2002002143A3 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
HK1076115A1 (en) Polyol-ifn-beta conjugates
DE60115405D1 (de) Verbesserungen in bezug auf ribosom-komplexe als selektionspartikel
HK1023513A1 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
EP1808155A3 (en) Antibody-serum protein hybrids
DK0450628T3 (da) Saccharidmidificerede, vandopløselæige proteiner
AU2236795A (en) Afamin: a human serum albumin-like protein
CA2373252A1 (en) Long lasting anti-angiogenic peptides
DE60223232D1 (de) Mucinpeptid mit immunstärkenden eigenschaften
Yuecel et al. Increased susceptibility to oxidative stress in lens tissues of sulfur dioxide exposed rats
WO1994015962A3 (en) Derivatized calcitonins
TW200619386A (en) Polyol-IFN-beta conjugates
AU2002300605A1 (en) Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20210206